{"protocolSection":{"identificationModule":{"nctId":"NCT00130039","orgStudyIdInfo":{"id":"TOSS-2"},"organization":{"fullName":"Asan Medical Center","class":"OTHER"},"briefTitle":"Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II","officialTitle":"Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel","acronym":"TOSS-2"},"statusModule":{"statusVerifiedDate":"2009-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-08"},"primaryCompletionDateStruct":{"date":"2009-01","type":"ACTUAL"},"completionDateStruct":{"date":"2009-01","type":"ACTUAL"},"studyFirstSubmitDate":"2005-08-11","studyFirstSubmitQcDate":"2005-08-12","studyFirstPostDateStruct":{"date":"2005-08-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-10-23","resultsFirstSubmitQcDate":"2009-11-27","resultsFirstPostDateStruct":{"date":"2010-01-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-01-04","lastUpdatePostDateStruct":{"date":"2010-01-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Sun U. Kwon","oldOrganization":"Asan Medical Center"},"leadSponsor":{"name":"Asan Medical Center","class":"OTHER"},"collaborators":[{"name":"Korea Otsuka International Asia Arab","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1 segment of Middle cerebral artery (MCA) or basilar artery).\n\nThey will be randomly assigned into cilostazol group or clopidogrel group. Every patients will take 100mg of aspirin a day additionally.\n\nThe primary outcome variable of this study is Progression rate of symptomatic intracranial stenosis on magnetic resonance angiogram (MRA).","detailedDescription":"\\[Goal\\] To Reveal the Effect and Safety of Cilostazol Compared with Clopidogrel on the Prevention of the Progression of Symptomatic Intracranial Arterial Stenosis.\n\n\\[Trial Design\\] Double-Blind, Active-Controlled, Randomized, Multicenter Trial\n\n\\[Participants\\] Acute ischemic stroke patients with symptomatic intracranial arterial stenosis\n\n\\[Methods\\]\n\n* Double-Blind, Active-Controlled, Randomized, Multicenter Trial\n* Investigational product (Double Dummy Method):\n\nCilostazol 200mg (100mg twice per day) versus clopidogrel 75mg\n\n* Concomitant medication: Aspirin 100 (75-150) mg per day\n* Medication Duration: 7 months\n\n\\[Outcome Variables\\]\n\nPrimary Outcome Variable:\n\n* Progression rate of symptomatic intracranial arterial stenosis\n\nSecondary outcome variables:\n\n* The occurrence of new MRI (magnetic resonance image) lesion on follow-up MRI\n* Stroke events\n* Overall cardiovascular events: stroke, acute coronary syndrome, vascular death\n* Ipsilateral ischemic stroke rate\n* Fatal or major bleeding complications"},"conditionsModule":{"conditions":["Cerebral Infarction","Atherosclerosis"],"keywords":["Infarction, Cerebral","cilostazol","stenosis","atherosclerosis","clopidogrel"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":457,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"cilostazol","type":"EXPERIMENTAL","description":"cilostazol 100mg bid plus placebo of clopidogrel","interventionNames":["Drug: Cilostazol"]},{"label":"Clopidogrel","type":"ACTIVE_COMPARATOR","description":"clopidogrel 75mg qd and matching placebo of cilostazol","interventionNames":["Drug: clopidogrel"]}],"interventions":[{"type":"DRUG","name":"clopidogrel","description":"Clopidogrel 75mg once a day plus placebo of cilostazol twice a day","armGroupLabels":["Clopidogrel"],"otherNames":["Plavix, produced by Sanofi-Aventis."]},{"type":"DRUG","name":"Cilostazol","description":"Cilostazol 100mg twice a day plus placebo of clopidogrel once a day","armGroupLabels":["cilostazol"],"otherNames":["cilostazol produced by Korea Otsuka Pharmaceutical"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Progression of Symptomatic Intracranial Stenosis","description":"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.\n\nThe progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA.","timeFrame":"7 months after treatment"}],"secondaryOutcomes":[{"measure":"Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI","description":"number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI.","timeFrame":"7 months after treatment"},{"measure":"Number of Participants With Stroke Events","description":"including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke","timeFrame":"upto 7 months after randomization"},{"measure":"Number of Participants With Overall Cardiovascular Events","description":"including nonfatal stroke, nonfatal myocardial infarction and vascular death.","timeFrame":"upto 7 months after randomization"},{"measure":"Number of Patients With Ipsilateral Ischemic Stroke Rate","description":"ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis","timeFrame":"upto 7 months after randomization"},{"measure":"Numbers of Fatal or Major Bleeding Complications","description":"life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood","timeFrame":"upto 7 months after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cerebral infarction within 2 weeks from the onset or TIA with corresponding acute ischemic brain lesions on MRI within 2 weeks from the onset\n* Age: more than 35 years of age\n* Patient with significant focal stenosis in the M1 segment of middle cerebral artery (MCA) or basilar artery (BA) with acute ischemic lesions on magnetic resonance imaging (MRI) within the vascular territory of the stenosed artery.\n\nExclusion Criteria:\n\n* Patients with any contraindications to the treatment with antiplatelet therapy\n* Patients with potential cardiac embolic source; prosthetic valve, atrial fibrillation, atrial flutter, left atrial/atrial appendage thrombus, sick sinus syndrome, left ventricular thrombus, dilated cardiomyopathy, akinetic or hypokinetic left ventricular segment, atrial myxoma, Infective endocarditis, mitral valve stenosis or prolapse, mitral annuls calcification, left atrial turbulence, nonbacterial endocarditis, congestive heart failure, recent myocardial infarction (within 4 weeks)\n* Patients with more than 50% stenosis in the parent artery of symptomatic stenosis\n* Bleeding diathesis\n* Chronic liver disease (ALT \\> 100 or AST \\> 100) or chronic renal disease (creatinine \\> 3.0mg/dl)\n* Anemia (hemoglobin \\< 10mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3)\n* Nonatherosclerotic vasculopathy; patients with clinical characteristics suggesting arterial dissection, moyamoya disease, Takayasu's arteritis, radiation associated angiopathy, and other vasculitis.\n* Severe stroke: NIH stroke scale : more than 16\n* Pregnant or lactating patients\n* Chronic user of NSAIDs\n* Thrombolytic therapy for the symptomatic stenosis\n* Symptomatic stenosis scheduled for angioplasty\n* Patients with pacemaker or any other contraindications to MRI","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Sun U. Kwon, MD, PhD","affiliation":"Asan Medical Center, Univsersity of Ulsan, Medical College","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Prince of Wales Hospital","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Queen Mary Hospital","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Konkuk Univ. Hospital","city":"Seoul","state":"Gwangjin-gu Hwayang-dong","zip":"143-729","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Inje University Ilsan Paik Hospital","city":"Goyang","state":"Gyeonggi-do","zip":"411-706","country":"Korea, Republic of","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Dongguk University International Hospital","city":"Goyang","state":"Kyoungki-do","zip":"410-773","country":"Korea, Republic of","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Hallym University Sacred Heart Hospital","city":"Anyang","state":"Kyunggi","zip":"430-070","country":"Korea, Republic of","geoPoint":{"lat":37.3925,"lon":126.92694}},{"facility":"Inha University Hospital","city":"Inchon","zip":"400-103","country":"Korea, Republic of","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam","country":"Korea, Republic of","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"110-744","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Kangdong Sacred Heart Hospital, Hallym University","city":"Seoul","zip":"134-701","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","zip":"135-710","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"138-736","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Soonchunhyang University Hospital","city":"Seoul","zip":"140-743","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul National University Boramae Hospital","city":"Seoul","zip":"156-707","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Eulji Hospital","city":"Seoul","zip":"280-1","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Philippine General Hospital","city":"Manila","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"facility":"University of Santo Tomas Hospital","city":"Manila","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"facility":"Ramathibodi Hospital","city":"Bangkok","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Siriraj Hospital","city":"Bangkok","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}}]},"referencesModule":{"references":[{"pmid":"24957314","type":"DERIVED","citation":"Park TH, Lee JS, Park SS, Ko Y, Lee SJ, Lee KB, Lee J, Kang K, Park JM, Choi JC, Kim DE, Cho YJ, Kim JT, Kim DH, Cha JK, Han MK, Lee J, Oh MS, Yu KH, Lee BC, Bae HJ, Hong KS. Safety and efficacy of intravenous recombinant tissue plasminogen activator administered in the 3- to 4.5-hour window in Korea. J Stroke Cerebrovasc Dis. 2014 Aug;23(7):1805-12. doi: 10.1016/j.jstrokecerebrovasdis.2014.04.027. Epub 2014 Jun 21."},{"pmid":"24315720","type":"DERIVED","citation":"Kim BJ, Rha JH, Kim SR, Kim DE, Kim HY, Lee JH, Bae HJ, Han MK, Kang DW, Ratanakorn D, Kim JS, Kwon SU. The effect of cilostazol on carotid intima-media thickness progression in patients with symptomatic intracranial atherosclerotic stenosis. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1164-70. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.007. Epub 2013 Dec 6."},{"pmid":"22910894","type":"DERIVED","citation":"Jung JM, Kang DW, Yu KH, Koo JS, Lee JH, Park JM, Hong KS, Cho YJ, Kim JS, Kwon SU; TOSS-2 Investigators. Predictors of recurrent stroke in patients with symptomatic intracranial arterial stenosis. Stroke. 2012 Oct;43(10):2785-7. doi: 10.1161/STROKEAHA.112.659185. Epub 2012 Aug 21."},{"pmid":"22539545","type":"DERIVED","citation":"Kim DE, Kim JY, Jeong SW, Cho YJ, Park JM, Lee JH, Kang DW, Yu KH, Bae HJ, Hong KS, Koo JS, Lee SH, Lee BC, Han MK, Rha JH, Lee YS, Kim GM, Chae SL, Kim JS, Kwon SU. Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study. Stroke. 2012 Jul;43(7):1824-30. doi: 10.1161/STROKEAHA.112.653659. Epub 2012 Apr 26. Erratum In: Stroke. 2013 Nov;44(11):158."},{"pmid":"21799173","type":"DERIVED","citation":"Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, Yu KH, Koo JS, Wong KS, Lee SH, Lee KB, Kim DE, Jeong SW, Bae HJ, Lee BC, Han MK, Rha JH, Kim HY, Mok VC, Lee YS, Kim GM, Suwanwela NC, Yun SC, Nah HW, Kim JS. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke. 2011 Oct;42(10):2883-90. doi: 10.1161/STROKEAHA.110.609370. Epub 2011 Jul 28."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"The excluded patients did not satisfy the definition of the symptomatic stenosis of our study protocol.","recruitmentDetails":"507 patients were registered www.toss2.com from 20 centers of 4 countries (Korea, Hongkong, Thailand, Philippines). 50 patients were excluded during case verification process because they did not satisfy patient's eligibility criteria.\n\nfinally 457 patients were randomized into cilostazol or clopidogrel group","groups":[{"id":"FG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel"},{"id":"FG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"232"},{"groupId":"FG001","numSubjects":"225"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"full analysis set","numSubjects":"202"},{"groupId":"FG001","comment":"full analysis set","numSubjects":"207"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"18"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"clinical events without follow up MRI","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel"},{"id":"BG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"232"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"457"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"205"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"252"}]}]}]},{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66.42","spread":"11.33"},{"groupId":"BG001","value":"64.58","spread":"11.11"},{"groupId":"BG002","value":"65.52","spread":"11.24"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"223"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"122"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"234"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Philippines","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}]}]},{"title":"Hong Kong","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"23"}]}]},{"title":"Thailand","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}]},{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"210"},{"groupId":"BG001","value":"203"},{"groupId":"BG002","value":"413"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Progression of Symptomatic Intracranial Stenosis","description":"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.\n\nThe progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA.","reportingStatus":"POSTED","anticipatedPostingDate":"2009-05","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"7 months after treatment","groups":[{"id":"OG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel"},{"id":"OG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"207"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"32"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI","description":"number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI.","populationDescription":"this analysis included the patients who had performed follow-up FLAIR imaging","reportingStatus":"POSTED","anticipatedPostingDate":"2009-05","paramType":"NUMBER","unitOfMeasure":"pariticipants","timeFrame":"7 months after treatment","groups":[{"id":"OG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel"},{"id":"OG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"191"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"23"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Stroke Events","description":"including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke","populationDescription":"this outcome analysis performed on the intention to treat (ITT) method","reportingStatus":"POSTED","anticipatedPostingDate":"2009-05","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"upto 7 months after randomization","groups":[{"id":"OG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel"},{"id":"OG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Overall Cardiovascular Events","description":"including nonfatal stroke, nonfatal myocardial infarction and vascular death.","populationDescription":"this outcome analysis was done intention to treat method","reportingStatus":"POSTED","anticipatedPostingDate":"2009-05","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"upto 7 months after randomization","groups":[{"id":"OG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel"},{"id":"OG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Ipsilateral Ischemic Stroke Rate","description":"ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis","populationDescription":"this outcome analysis was done ITT method","reportingStatus":"POSTED","anticipatedPostingDate":"2009-05","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"upto 7 months after randomization","groups":[{"id":"OG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel"},{"id":"OG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Numbers of Fatal or Major Bleeding Complications","description":"life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood","populationDescription":"this outcome analysis was done ITT method","reportingStatus":"POSTED","anticipatedPostingDate":"2009-05","paramType":"NUMBER","unitOfMeasure":"events","timeFrame":"upto 7 months after randomization","groups":[{"id":"OG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel"},{"id":"OG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"Cilostazol","description":"cilostazol 100mg twice a day plus placebo of clopidogrel","seriousNumAffected":54,"seriousNumAtRisk":232,"otherNumAffected":232,"otherNumAtRisk":232},{"id":"EG001","title":"Clopidogrel","description":"clopidogrel 75mg per day and matching placebo of cilostazol","seriousNumAffected":54,"seriousNumAtRisk":225,"otherNumAffected":225,"otherNumAtRisk":225}],"seriousEvents":[{"term":"'Blood tinged loose stool","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"multi-organ failure","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"abnormal involuntary movement","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"acute bronchitis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"acute myocardial infarction","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":232},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"cerebral infarction","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":232},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":225}]},{"term":"cerebral hemorrhage","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"aneurysm unruptured","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"gastroenteritis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":232},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":225}]},{"term":"cardiac arrest","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"GI bleeding","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":232},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":225}]},{"term":"traffic accident","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"otitis media","organSystem":"Ear and labyrinth disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"cystitis","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"cataract operation","organSystem":"Eye disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":232},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"depression","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":232},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":225}]},{"term":"diabetes complications","organSystem":"Endocrine disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":232},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":225}]},{"term":"general weakness","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"vestibular neuronitis","organSystem":"Ear and labyrinth disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"fracture or other joint pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":232},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":225}]},{"term":"infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"headache","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"edema","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"tachycardia","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"seizure","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"severe hypertension","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":232},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":225}]}],"otherEvents":[{"term":"headache","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":62,"numAtRisk":232},{"groupId":"EG001","numEvents":42,"numAffected":35,"numAtRisk":225}]},{"term":"diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":232},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":225}]},{"term":"petechia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":232},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"dizziness","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":28,"numAtRisk":232},{"groupId":"EG001","numEvents":23,"numAffected":21,"numAtRisk":225}]},{"term":"palpitation","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":232},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"urticaria","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":232},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"epigastric soreness","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":232},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":225}]},{"term":"GI bleedings","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":232},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"others","organSystem":"Social circumstances","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":565,"numAffected":169,"numAtRisk":232},{"groupId":"EG001","numEvents":564,"numAffected":225,"numAtRisk":225}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Sun U. Kwon, MD, PhD, Prof","organization":"Asan Medical Center, University of Ulsan","email":"sukwon@amc.seoul.kr","phone":"82-2-3010-3960"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000050197","term":"Atherosclerosis"},{"id":"D000007238","term":"Infarction"},{"id":"D000003251","term":"Constriction, Pathologic"}],"ancestors":[{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020763","term":"Pathological Conditions, Anatomical"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020521","term":"Stroke"}],"browseLeaves":[{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M25878","name":"Atherosclerosis","asFound":"Atherosclerosis","relevance":"HIGH"},{"id":"M20249","name":"Disease Progression","relevance":"LOW"},{"id":"M6165","name":"Constriction, Pathologic","asFound":"Stenosis","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M22209","name":"Pathological Conditions, Anatomical","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077407","term":"Cilostazol"},{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000001993","term":"Bronchodilator Agents"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000018927","term":"Anti-Asthmatic Agents"},{"id":"D000019141","term":"Respiratory System Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000014665","term":"Vasodilator Agents"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000058987","term":"Phosphodiesterase 3 Inhibitors"},{"id":"D000010726","term":"Phosphodiesterase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M1669","name":"Clopidogrel","asFound":"Results","relevance":"HIGH"},{"id":"M1788","name":"Cilostazol","asFound":"Stored","relevance":"HIGH"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M4959","name":"Bronchodilator Agents","relevance":"LOW"},{"id":"M20653","name":"Anti-Asthmatic Agents","relevance":"LOW"},{"id":"M20827","name":"Respiratory System Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M29023","name":"Phosphodiesterase 3 Inhibitors","relevance":"LOW"},{"id":"M13319","name":"Phosphodiesterase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"Resp","name":"Respiratory System Agents"}]}},"hasResults":true}